ACADIA Pharmaceuticals Inc.
ACAD
$16.12
-$0.50-3.01%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 259.60M | 250.40M | 241.96M | 205.83M | 231.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 259.60M | 250.40M | 241.96M | 205.83M | 231.04M |
| Cost of Revenue | 122.53M | 85.46M | 94.46M | 82.63M | 84.63M |
| Gross Profit | 137.07M | 164.94M | 147.50M | 123.20M | 146.41M |
| SG&A Expenses | 130.08M | 118.39M | 117.06M | 107.99M | 111.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 252.61M | 203.86M | 211.53M | 190.62M | 196.10M |
| Operating Income | 6.99M | 46.54M | 30.44M | 15.21M | 34.94M |
| Income Before Tax | 161.09M | 38.81M | 37.18M | 21.00M | 39.70M |
| Income Tax Expenses | 17.34M | 6.04M | 3.79M | 4.45M | -6.09M |
| Earnings from Continuing Operations | 143.74M | 32.77M | 33.39M | 16.56M | 45.80M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 143.74M | 32.77M | 33.39M | 16.56M | 45.80M |
| EBIT | 6.99M | 46.54M | 30.44M | 15.21M | 34.94M |
| EBITDA | 12.20M | 49.11M | 33.01M | 20.74M | 36.58M |
| EPS Basic | 0.86 | 0.20 | 0.20 | 0.10 | 0.28 |
| Normalized Basic EPS | 0.05 | 0.20 | 0.14 | 0.08 | 0.13 |
| EPS Diluted | 0.86 | 0.20 | 0.20 | 0.10 | 0.27 |
| Normalized Diluted EPS | 0.05 | 0.20 | 0.14 | 0.08 | 0.13 |
| Average Basic Shares Outstanding | 166.54M | 165.97M | 165.55M | 164.80M | 164.81M |
| Average Diluted Shares Outstanding | 166.70M | 166.18M | 166.17M | 166.62M | 166.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
